Thrombotic microangiopathy following a stem cell transplant is a rare but serious complication that often leads to progressive organ damage and death. Akari is …
Akari Therapeutics Narrows Pipeline Focus
NEW YORK and LONDON, August 1, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies …
[Read more...] about Akari Therapeutics Narrows Pipeline Focus
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
Positive results from recent pre-clinical studies support the potential of long-acting PASylated® nomacopan to advance toward IND/IMPD for clinical trials in …
Akari Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Pipeline Progress
Four patients have been enrolled in the Phase 3 Part A clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant related (HSCT) …
Akari Therapeutics Announces First Patient to Complete Course of Treatment in the Phase III Part A Clinical Trial of Investigational Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)
NEW YORK and LONDON, July 7, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for …
